CureVac EBITDA 2021-2024 | CVAC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

CureVac ebitda from 2021 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

CureVac ebitda from 2021 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$147B
Gilead Sciences (GILD)	$116B
Bristol Myers Squibb (BMY)	$115.8B
Vertex Pharmaceuticals (VRTX)	$110.2B
CSL (CSLLY)	$81.9B
Regeneron Pharmaceuticals (REGN)	$74.7B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$38.6B
Alnylam Pharmaceuticals (ALNY)	$34.4B
BioNTech SE (BNTX)	$27.6B
Illumina (ILMN)	$22.3B
BeiGene (ONC)	$21.7B
Biogen (BIIB)	$20.8B
Moderna (MRNA)	$14.8B
Insmed (INSM)	$14B
Incyte (INCY)	$13.9B
Genmab (GMAB)	$13.9B
Genmab (GNMSF)	$13.9B
Intra-Cellular Therapies (ITCI)	$13.5B
Bio-Techne Corp (TECH)	$12.5B
BioMarin Pharmaceutical (BMRN)	$11.8B
Sarepta Therapeutics (SRPT)	$11.1B
Vaxcyte (PCVX)	$10.8B
QIAGEN (QGEN)	$10.8B
Exact Sciences (EXAS)	$10.1B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Bio-Rad Laboratories (BIO.B)	$9.8B
Exelixis (EXEL)	$9.4B
Repligen (RGEN)	$9.3B
Roivant Sciences (ROIV)	$8.1B